310 related articles for article (PubMed ID: 17889351)
41. Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study.
Ness KK; Bhatia S; Baker KS; Francisco L; Carter A; Forman SJ; Robison LL; Rosenthal J; Gurney JG
Arch Pediatr Adolesc Med; 2005 Aug; 159(8):706-13. PubMed ID: 16061776
[TBL] [Abstract][Full Text] [Related]
42. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
43. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
[TBL] [Abstract][Full Text] [Related]
44. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
45. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
46. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens.
Gutierrez-Delgado F; Maloney DG; Press OW; Golden J; Holmberg LA; Maziarz RT; Hooper H; Buckner CD; Appelbaum FR; Bensinger WI
Bone Marrow Transplant; 2001 Sep; 28(5):455-61. PubMed ID: 11593318
[TBL] [Abstract][Full Text] [Related]
47. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
49. Health care utilization by adult long-term survivors of hematopoietic cell transplant: report from the Bone Marrow Transplant Survivor Study.
Shankar SM; Carter A; Sun CL; Francisco L; Baker KS; Gurney JG; Weisdorf DG; Forman SJ; Robison LL; Grant M; Bhatia S
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):834-9. PubMed ID: 17416780
[TBL] [Abstract][Full Text] [Related]
50. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
51. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
[TBL] [Abstract][Full Text] [Related]
52. Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.
Broun ER; Tricot G; Akard L; Nichols C; Cheerva A; Jansen J
Bone Marrow Transplant; 1990 May; 5(5):341-4. PubMed ID: 2190660
[TBL] [Abstract][Full Text] [Related]
53. Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation.
Jules-Elysee K; Stover DE; Yahalom J; White DA; Gulati SC
Am Rev Respir Dis; 1992 Aug; 146(2):485-91. PubMed ID: 1489145
[TBL] [Abstract][Full Text] [Related]
54. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
55. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
[TBL] [Abstract][Full Text] [Related]
56. Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation.
Armenian SH; Iukuridze A; Teh JB; Mascarenhas K; Herrera A; McCune JS; Zain JM; Mostoufi-Moab S; McCormack S; Slavin TP; Scott JM; Jones LW; Sun CL; Forman SJ; Wong FL; Nakamura R
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):962-972. PubMed ID: 32212263
[TBL] [Abstract][Full Text] [Related]
57. Health care utilization by adult Hispanic long-term survivors of hematopoietic stem cell transplantation: report from the Bone Marrow Transplant Survivor Study.
Prasad PK; Sun CL; Baker KS; Francisco L; Forman S; Bhatia S; Shankar SM
Cancer; 2008 Nov; 113(10):2724-33. PubMed ID: 18831512
[TBL] [Abstract][Full Text] [Related]
58. Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study.
Murbraech K; Wethal T; Smeland KB; Holte H; Loge JH; Holte E; Rösner A; Dalen H; Kiserud CE; Aakhus S
JACC Cardiovasc Imaging; 2016 Mar; 9(3):230-9. PubMed ID: 26897666
[TBL] [Abstract][Full Text] [Related]
59. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.
Khera N; Storer B; Flowers ME; Carpenter PA; Inamoto Y; Sandmaier BM; Martin PJ; Lee SJ
J Clin Oncol; 2012 Jan; 30(1):71-7. PubMed ID: 22147737
[TBL] [Abstract][Full Text] [Related]
60. Cognitive Functioning in Survivors of Hematopoietic Stem Cell Transplantation Compared With a Matched General Population Sample-The Maastricht Observational Study of Late Effects After Stem Cell trAnsplantation Study.
Wauben B; van der Poel MWM; Greevenbroek MMJ; van Yperen NC; Schram MT; van Boxtel MPJ; Sastry M; Simons SO; Stehouwer CDA; Dagnelie PC; Wesselius A; Schouten HC; Köhler S
Transplant Cell Ther; 2023 Jul; 29(7):468.e1-468.e8. PubMed ID: 36966872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
